Cancer Research  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 3744-3748, September 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, K.-H.
Right arrow Articles by Cha, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, K.-H.
Right arrow Articles by Cha, S.

Inhibition of Nucleoside Transport in Murine Lymphoma L5178Y Cells and Human Erythrocytes by the Uridine Phosphorylase Inhibitors 5-Benzylacyclouridine and 5-Benzyloxybenzylacyclouridine1

Kang-Hyun Lee2, Mahmoud H. el Kouni, Shih-Hsi Chu and Sungman Cha3

Division of Biology and Medicine, Brown University, Providence, Rhode Island 02912

The uridine phosphorylase inhibitors, 5-benzylacyclouridine (BAU) and 5-benzyloxybenzylacyclouridine (BBAU) (Biochem. Pharmacol., 31: 1857, 1982), inhibited uptake of uridine in L5178Y cells. By a rapid sampling technique, BAU and BBAU were shown to inhibit the transport (zero-trans influx) of uridine, thymidine, and adenosine in human erythrocytes as well as in murine L5178Y cells. In all cases, competitive inhibitions were observed. Km values for the transport of adenosine, uridine, and thymidine in erythrocytes were 2.2, 195, and 199 µM, while Vmax were 2.9, 118, and 96.5 pmol/min/106 cells, respectively. In L5178Y cells, Km values of 14.8 and 23.1 µM and Vmax of 389 and 176 pmol/min/106 cells were obtained for adenosine and uridine, respectively. For erythrocytes, the Ki values of BAU were 127, 124, and 198 µM using adenosine, uridine, and thymidine as the substrate; and those of BBAU, 14.1 and 19.2 µM for adenosine and uridine, respectively. In L5178Y, the Ki values of BAU were 202 and 234 µM, and those of BBAU, 39.8 and 27.9 µM for adenosine and uridine, respectively. These data indicate that, in two cell types, Ki values for BAU and BBAU did not vary regardless of the substrate used; that the values of Ki are different for the erythrocytes and L5178Y cells; and that BBAU is at least 5-fold more potent than BAU as an inhibitor of nucleoside transport. The inhibitory effects on the efflux of preloaded uridine indicate that BAU and BBAU are inhibitors, rather than permeants, of the nucleoside transport system.

1 Supported by Grant CH-136 awarded by the American Cancer Society and by Grants CA-13943 and CA-31650 awarded by the National Cancer Institute, Department of Health and Human Services.

2 Recipient of support from the training program in cancer research, USPHS Grant CA 09204, awarded by the National Cancer Institute, Department of Health and Human Services.

3 To whom requests for reprints should be addressed.

Received 8/30/83. Accepted 5/23/84.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.